US Brand Drug Prices Grew At Historically Low Rates In 2018 – IQVIA
Net price growth of 0.3% for branded drugs in 2018 was 1.6% below Consumer Price Index inflation, while invoice prices grew an average of 5.5%.
You may also be interested in...
HHS downplays latest attempt to predict “complex behavior changes to a broken system.”
Pharma is facing a big headwind in 2019 in the form of diminished drug pricing power. The pricing trend puts net drug prices squarely in the red for most large pharma manufacturers, but US lawmakers aren't likely to be reassured heading into an upcoming hearing on drug pricing.
Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.